Ionis grants Dynacure rights to musculoskeletal candidate IONIS-DNM2-2.5Rx

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) granted Dynacure S.A.S. (Illkirch, France) rights to develop and commercialize IONIS-DNM2-2.5Rx (DYN101). Dynacure is developing the antisense oligonucleotide targeting the mRNA of dynamin 2 (DNM2) to treat centronuclear myopathy (CNM), a group of rare genetic muscle diseases that affect children and young adults.

Ionis received an equity stake in Dynacure valued at $5 million, and is eligible for $205 million in milestones, either as cash or equity, plus undisclosed royalties...